<DOC>
	<DOCNO>NCT00381667</DOCNO>
	<brief_summary>This study GW642444M , long-acting beta 2 specific agonist . This study examine GW642444M via inhale route ass efficacy , safety , tolerability , pharmacodynamics pharmacokinetics single administration three inhaled dos ( 25 , 100 400 µg ) GW642444M persistent asthmatic . This study single-centre , placebo-controlled , dose-ascending , five-way crossover 30 asthmatic patient . Key assessment : efficacy , safety , tolerability , pharmacokinetics pharmacodynamics assess measurement FEV1 , blood pressure , pulse rate , 12-lead ECGs , clinical laboratory safety test , collection adverse event blood sample .</brief_summary>
	<brief_title>Study Assess GW642444 Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion criterion : Subjects document history persistent asthma , exclusion significant pulmonary disease Female subject nonchild bear potential ( i.e . postmenopausal surgically sterile ) Subjects current nonsmoker , use inhale tobacco product ( snuff permit ) 12 month period precede screen visit pack history le 10 pack year . Subjects clinically stable persistent asthma within 4 week precede screen visit screen prebronchodilator FEV1 60 90 % predict ( abstained bronchodilator require period ) . Predicted value base ECCS 1993 normal range During screen visit , subject must demonstrate presence reversible airway disease , define increase FEV1 great 12.0 % baseline absolute change great 300 mL within 30 minute follow single 400 mcg salbutamol dose . Subjects currently take ICS total daily dose 200 500 mcg FP equivalent ICS Exclusion criterion : Subjects past present disease , judge Investigator Medical Monitor , may affect safety subject outcome study A screening Holter ECG trace reveals clinically concern arrhythmia ( include , limited , ventricular ectopic run 4 beat , R T phenomenon , bigeminy , trigeminy ) . A mean QTc ( B ) value screen &gt; 430 msec ( male ) / &gt; 450 msec ( female ) ECG suitable QT measurement ( e.g . poorly define termination T wave ) . Any adverse reaction include immediate delay hypersensitivity ß2 agonist sympathomimetic drug , know suspected sensitivity constituent GW642444 inhalation powder ( e.g. , lactose COA ) . Subjects weigh &lt; 50 kg Subjects participate GSK study involve administration COA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>GW642444M</keyword>
	<keyword>Single Dose</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>GW642444H</keyword>
	<keyword>tolerability</keyword>
</DOC>